Search our Database of Scientific Publications and Authors

I’m looking for a

    Details and Download Full Text PDF:
    Effective treatment of aggressive fibromatosis with celecoxib guided by genetic testing.

    Cancer Biol Ther 2017 Oct 7;18(10):757-760. Epub 2017 Sep 7.
    a Department of Oncology , The Affiliated Hospital of Qingdao University , Qingdao , Shandong , China.
    Aggressive fibromatosis (AF) or desmoid tumors is an aggressive fibroblastic proliferation which is locally invasive but can not metastasize. The treatment of AF is challenging. Surgery was the main treatment modality for AF in the past, other strategies including radiotherapy, systemic therapies and wait-and-see policy. The use of non-steroidal anti-inflammatory drugs (NSAIDs) and targeted therapies has demonstrated good results. In the case report, a 39-year-old man presented with progressive chest wall pain. Computed tomography (CT) showed an approximately 46× 13 mm soft-tissue mass between the inside of the fifth and sixth rib on the right side. The entire mass was excised and an AF was confirmed based on histopathology. Four months after surgery, magnetic resonance imaging (MRI) showed a soft-tissue mass in surgical areas and biopsy confirmed local recurrence. Therefore, Tomotherapy was administered. However, two months later, an (18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography combined with CT (PET-CT) revealed the presence of an FDG-avid mass in the area of local recurrence. Genetic testing reported the presence of a p.T41A mutations on the CTNNB1 gene, which predicted that he is sensitive to the COX-2 inhibitor celecoxib. The tumor regressed rapidly after the application of celecoxib. Within the 20-month follow-up period, the patient showed remarkable regression without any signs and symptoms. Our case report provides further evidence for the efficacy of celecoxib in AF with CTNNB1 gene mutations. To our knowledge, this is the first report of AF treated with celecoxib under the guidance of the genetic testing. However, further studies are required.
    PDF Download - Full Text Link
    ( Please be advised that this article is hosted on an external website not affiliated with
    Source Status ListingPossible

    Similar Publications

    Complete remission of pancreatic head desmoid tumor treated by COX-2 inhibitor-a case report.
    World J Surg Oncol 2016 Jul 22;14(1):190. Epub 2016 Jul 22.
    Division of General Surgery, Department of Surgery, Cathay General Hospital, Taipei, Taiwan.
    Background: Desmoid tumors (DTs) are non-metastatic, locally aggressive neoplasms with high postoperative recurrence rates. The pancreas is an extremely rare location for DTs. The local control of DTs is challenging. Read More
    Imaging features of desmoid-type fibromatosis in the teres major muscle.
    In Vivo 2013 Jul-Aug;27(4):555-9
    Department of Orthopaedic Surgery, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.
    Desmoid-type fibromatosis is a locally aggressive fibroblastic neoplasm with a tendency for local recurrence, despite adequate surgical resection. Its clinical presentation, biological behavior, and natural history can vary considerably. We present a unique case of desmoid-type fibromatosis arising in the left teres major muscle of a 62-year-old female. Read More
    Desmoid-Type Fibromatosis of the Thorax: CT, MRI, and FDG PET Characteristics in a Large Series From a Tertiary Referral Center.
    Medicine (Baltimore) 2015 Sep;94(38):e1547
    From the Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (HX, HJK, SL, JWL, HNL, MYK); Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China (HX); Department of Thoracic and Cardiovascular Surgery (DKK); and Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea (JSS).
    The purpose of this study was to describe the radiologic findings of computed tomography (CT), magnetic resonance (MR) imaging, and ¹⁸F-fluorodeoxy glucose positron emission tomography (FDG PET) in desmoid-type fibromatosis of the thorax. We retrospectively evaluated 47 consecutive patients with pathologically proven desmoid-type fibromatosis from January 2005 to March 2015. Patients underwent CT (n = 36) and/or MR (n = 32), and 13 patients also underwent FDG PET. Read More
    Prognostic value of CTNNB1 gene mutation in primary sporadic aggressive fibromatosis.
    Ann Surg Oncol 2015 May 24;22(5):1464-70. Epub 2014 Oct 24.
    Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands,
    Background: Aggressive fibromatosis (AF) comprises tumors with a varying biological behavior. Genetic tumor characteristics may be predictive of recurrence; hence, the prognostic value of three specific mutations on the CTNNB1 gene was evaluated in relation to known clinicopathologic risk factors in patients with primary, sporadic AF.

    Methods: In a multi-institutional retrospective cohort study of patients with primary extra-abdominal and abdominal wall AF who underwent surgical treatment, the original pathology specimens were reviewed for the presence of a T41A, S45F, and 45P mutations on the CTNNB1 gene. Read More